Desloratadine Oral Solution

For adults and adolescents aged 12 years and older, the standard recommended dose of desloratadine is 5 mg taken once daily. This dosage applies to all primary indications, including seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria.

Clinical trials have demonstrated that increasing the dose beyond 5 mg does not typically result in increased efficacy but may increase the risk of side effects, such as somnolence (drowsiness). Therefore, patients should strictly adhere to the 5 mg once-daily limit unless otherwise directed by a physician.

Desloratadine is approved for use in pediatric patients, but the dosage is strictly age-dependent. Healthcare providers use the following guidelines:

• Children 6 to 11 years of age: The recommended dose is 2.5 mg (either half of a 5 mg tablet, one 2.5 mg ODT, or 5 mL of oral solution) once daily.
• Children 12 months to 5 years of age: The recommended dose is 1.25 mg (2.5 mL of oral solution) once daily.
• Infants 6 months to 11 months of age: The recommended dose is 1.0 mg (2 mL of oral solution) once daily.

The safety and efficacy of desloratadine in children under 6 months of age have not been established. Always use a calibrated measuring device (such as an oral syringe) for the liquid formulation to ensure the child receives the correct dose.

Renal Impairment

In patients with compromised kidney function, the body may take longer to clear desloratadine. For adults with either permanent or temporary renal impairment, a starting dose of 5 mg every other day is often recommended. This adjustment helps prevent the accumulation of the drug to potentially toxic levels.

Hepatic Impairment

Because desloratadine is extensively metabolized by the liver, patients with hepatic (liver) insufficiency require cautious dosing. Similar to renal impairment, a starting dose of 5 mg every other day is generally recommended for adults with liver disease.

Elderly Patients

While no specific dosage adjustment is universally required for the elderly based solely on age, healthcare providers should be mindful that older patients are more likely to have decreased renal or hepatic function. Dosing should be initiated at the lower end of the range, and kidney function should be monitored.

• Consistency: Desloratadine can be taken with or without food. It is best to take it at the same time each day to maintain a steady level of the medication in your bloodstream.
• Orally Disintegrating Tablets (ODT): If using the ODT form, place the tablet on the tongue and allow it to dissolve. It can be swallowed with or without water. Do not remove the tablet from the blister pack until immediately before use.
• Oral Solution: Use the provided dosing cup or a medicinal syringe. Household teaspoons are not accurate for measuring medication.
• Storage: Store desloratadine at room temperature, typically between 68°F and 77°F (20°C to 25°C). Keep the medication away from excessive moisture and heat.

If you miss a dose of desloratadine, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects.

In the event of an overdose, patients may experience exaggerated side effects, most notably extreme drowsiness (somnolence), rapid heart rate (tachycardia), and headache.

Emergency Measures: If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally symptomatic and supportive. Desloratadine is not removed by hemodialysis (a procedure to clean the blood), so supportive care is the primary intervention.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication without medical guidance, especially if you are using it to manage a chronic condition like urticaria.

Desloratadine is generally well-tolerated, and most side effects are mild and transient. In clinical trials, the incidence of side effects was only slightly higher than that of a placebo. The most frequently reported common side effects in adults include:

• Pharyngitis (Sore Throat): This is the most common complaint, often described as a scratchy or dry sensation in the throat. It usually resolves within a few days of starting the medication.
• Dry Mouth (Xerostomia): Because desloratadine has very slight anticholinergic activity, it can reduce saliva production. Patients may find relief by sipping water or using sugarless lozenges.
• Fatigue and Somnolence: Although desloratadine is classified as non-sedating, a small percentage of patients (about 2-5%) may still feel slightly tired or drowsy, especially at the beginning of treatment.

These side effects occur less frequently but are still documented in clinical literature:

• Myalgia (Muscle Pain): Some patients report generalized muscle aches or soreness.
• Dysmenorrhea (Painful Menstruation): In clinical trials, a slightly higher incidence of menstrual cramping was noted in women taking desloratadine compared to placebo.
• Dyspepsia (Indigestion): Mild stomach upset, nausea, or a feeling of fullness after eating may occur.
• Dizziness: A feeling of lightheadedness or unsteadiness, which usually passes as the body adjusts to the drug.

Rarely, patients may experience more unusual reactions, including:

• Tachycardia (Rapid Heartbeat): A sensation of the heart racing or pounding in the chest.
• Increased Liver Enzymes: Asymptomatic elevations in liver function tests (ALT, AST, and bilirubin) have been reported.
• Hypersensitivity Reactions: This includes mild rashes or pruritus (itching) that is not related to the original condition being treated.

While extremely rare, serious adverse events can occur. You should stop taking desloratadine and seek emergency care if you experience:

• Anaphylaxis: A severe, life-threatening allergic reaction characterized by swelling of the face, lips, tongue, or throat, difficulty breathing (dyspnea), and a sudden drop in blood pressure.
• Seizures: There have been rare post-marketing reports of seizures in patients taking desloratadine, particularly those with a pre-existing history of epilepsy.
• Hepatitis (Liver Inflammation): Symptoms include yellowing of the skin or eyes (jaundice), dark urine, severe abdominal pain, and persistent nausea.
• Severe Palpitations: Irregular heart rhythms or a feeling that the heart is skipping beats.

> Warning: Stop taking Desloratadine and call your doctor immediately if you experience any signs of a severe allergic reaction or liver dysfunction.

Desloratadine has been studied for long-term use, particularly in patients with chronic idiopathic urticaria. Data suggests that the drug maintains its efficacy over several months without the development of tolerance (where the drug becomes less effective over time). There is no evidence that long-term use of desloratadine causes organ damage or cumulative toxicity in healthy individuals. However, long-term users should still have periodic check-ups with their healthcare provider to ensure the medication remains appropriate for their needs.

As of 2024, there are no FDA black box warnings for desloratadine. It is considered to have a high safety margin when used as directed. Unlike some older antihistamines (like terfenadine), desloratadine does not have a significant risk of causing dangerous 'torsades de pointes' heart rhythms at therapeutic doses.

Report any unusual symptoms or persistent side effects to your healthcare provider. Even mild side effects can be managed with professional guidance, such as adjusting the time of day the medication is taken.

Desloratadine is a highly effective antihistamine, but it is not suitable for everyone. Before starting this medication, it is vital to disclose your full medical history to your healthcare provider. While it is marketed as non-drowsy, individual responses vary. Some people may experience a degree of somnolence (sleepiness) that could impair their ability to perform complex tasks.

No FDA black box warnings for Desloratadine. This medication is generally considered safe for the broad population when used according to the prescribed or labeled instructions.

• Allergic Reactions / Anaphylaxis Risk: Patients who have had a previous hypersensitivity reaction to loratadine (Claritin) should not take desloratadine, as the two drugs are chemically related, and cross-sensitivity is highly likely. Signs of a reaction include hives, swelling, and difficulty breathing.
• Renal and Hepatic Impairment: Patients with significant kidney or liver disease are at risk for drug accumulation. Desloratadine is primarily metabolized by the liver and excreted by the kidneys. In these populations, the dosing frequency must be reduced (typically to every other day) to avoid adverse effects.
• Phenylketonuria (PKU) Warning: The orally disintegrating tablet (ODT) formulation of desloratadine often contains aspartame, which is a source of phenylalanine. Patients with PKU must be aware of this and may need to use the standard tablet or syrup instead.
• Seizure Disorders: Although rare, desloratadine has been associated with an increased risk of seizures in vulnerable individuals. Use with extreme caution in patients with a history of epilepsy or those taking other medications that lower the seizure threshold.

For the vast majority of patients, routine laboratory monitoring is not required while taking desloratadine. However, in specific cases, a healthcare provider may order:

• Liver Function Tests (LFTs): If a patient develops symptoms of liver distress (jaundice, upper right abdominal pain).
• Kidney Function (Creatinine/BUN): Especially in elderly patients or those with known renal disease, to ensure the dosing interval remains appropriate.

In clinical trials, desloratadine at the recommended 5 mg dose did not produce impairment of psychomotor performance. However, because individual sensitivity to antihistamines varies, patients should be cautious when driving or operating heavy machinery until they are certain the medication does not make them feel drowsy or dizzy. Combining desloratadine with alcohol or other CNS depressants can significantly increase the risk of impairment.

While desloratadine does not have the potent sedative-potentiating effects of first-generation antihistamines, it is still generally advised to limit alcohol consumption while taking this medication. Alcohol can worsen dizziness or fatigue, and in some individuals, the combination may lead to unexpected levels of drowsiness.

Desloratadine does not typically require a tapering schedule. It can usually be stopped abruptly without the risk of a withdrawal syndrome. However, if you are taking it for chronic hives, stopping the medication may result in a return of the itching and wheals. If you are undergoing allergy skin testing, you must stop taking desloratadine at least 48 to 72 hours (and sometimes up to a week) before the test, as antihistamines will suppress the skin's reaction to allergens, leading to false-negative results.

> Important: Discuss all your medical conditions, including any history of kidney or liver disease, with your healthcare provider before starting Desloratadine.

There are no drugs that are strictly 'contraindicated' (never to be used) with desloratadine in the same way that some drugs interact with MAO inhibitors. However, desloratadine should not be used in combination with loratadine, as desloratadine is the active metabolite of loratadine. Taking both simultaneously is essentially a double-dose of the same active compound, significantly increasing the risk of toxicity and side effects.

• Ketoconazole and Erythromycin: These medications are potent inhibitors of the CYP3A4 enzyme system. When co-administered with desloratadine, they can increase the plasma concentration of desloratadine by 45% to 75%. While these increases have not been shown to cause clinically significant changes in the heart's electrical activity (QT interval), patients should be monitored for increased side effects like dry mouth and drowsiness.
• Azithromycin: Similar to erythromycin, azithromycin can increase desloratadine levels, though to a slightly lesser extent. Clinical monitoring is advised.
• Cimetidine: This H2-blocker used for acid reflux can increase desloratadine concentrations by about 45%. While generally safe, the combination may increase the likelihood of minor side effects.

• CNS Depressants: This includes benzodiazepines (like diazepam), opioid pain medications, and certain sleep aids. Although desloratadine is non-sedating, adding it to a regimen of other sedating drugs can have an additive effect in sensitive individuals.
• Anticholinergic Drugs: Medications used for overactive bladder or COPD (like ipratropium) may have additive drying effects when taken with desloratadine, leading to severe dry mouth or constipation.

• Grapefruit Juice: Unlike many other drugs that are metabolized by the CYP3A4 system, desloratadine's metabolism is not significantly altered by grapefruit juice. Clinical studies showed no meaningful change in the drug's profile when taken with grapefruit juice.
• High-Fat Meals: Food does not affect the bioavailability or the peak concentration of desloratadine. It can be taken safely on an empty or full stomach.

• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4. It may potentially decrease the blood levels of desloratadine, making the allergy medication less effective.
• Valerian and Kava: These herbs have sedative properties. While no direct interaction exists, they may increase the risk of sleepiness if taken alongside desloratadine.

• Allergy Skin Tests: Desloratadine will prevent or diminish positive reactions to dermal reactivity indicators. It must be discontinued several days before any skin prick or intradermal allergy testing to ensure accurate results.

Mechanism of Interactions

Most interactions with desloratadine occur through the inhibition of metabolic enzymes (CYP3A4 and CYP2D6). When these enzymes are blocked by another drug (like ketoconazole), the body cannot break down desloratadine as quickly, leading to higher levels in the blood. Conversely, enzyme inducers (like St. John's Wort) speed up the breakdown, reducing efficacy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is the best way to prevent adverse drug-drug interactions.

There are few absolute contraindications for desloratadine, but they are critical for patient safety:

• Hypersensitivity to Desloratadine: If a patient has previously experienced an allergic reaction (such as anaphylaxis, angioedema, or severe rash) to desloratadine, they must never take it again.
• Hypersensitivity to Loratadine: Because desloratadine is the primary metabolite of loratadine, patients who are allergic to Claritin (loratadine) are almost certain to be allergic to desloratadine. This is due to the nearly identical chemical structure of the two molecules.

These are conditions where the drug may be used, but only after a careful risk-benefit analysis by a healthcare professional:

• Severe Renal Impairment (GFR < 30 mL/min): While not strictly forbidden, the risk of drug accumulation is high. If used, the dosing interval must be adjusted to every other day, and the patient must be monitored closely for signs of toxicity.
• Severe Hepatic Insufficiency: Similar to renal impairment, the liver's inability to process the drug requires a reduced dosing frequency.
• Pregnancy: Desloratadine is generally avoided unless the benefit to the mother clearly outweighs the potential risk to the fetus, as comprehensive human data is limited.
• Seizure History: Because of rare reports of seizures, physicians may prefer alternative antihistamines for patients with poorly controlled epilepsy.

Patients should be aware of cross-sensitivity within the piperidine class of antihistamines. While desloratadine is highly specific, individuals who have had severe reactions to other second-generation antihistamines should approach desloratadine with caution. There is no known cross-sensitivity between desloratadine and first-generation antihistamines like diphenhydramine (Benadryl) or chlorpheniramine.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies, before prescribing Desloratadine. Always wear a medical alert bracelet if you have a known severe allergy to any medication.

Desloratadine was previously classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. In animal studies using doses much higher than the human therapeutic dose, some instances of decreased pup survival and decreased body weight were noted.

Healthcare providers typically recommend using desloratadine during pregnancy only if the symptoms are severe and other, more extensively studied options (like cetirizine or loratadine) are not preferred. Use during the first trimester is generally approached with the most caution.

Desloratadine and its metabolite, 3-hydroxydesloratadine, are excreted into breast milk. The amount of drug the infant receives is estimated to be very low. However, because antihistamines can potentially decrease milk production (especially if combined with a decongestant) and because of the potential for the infant to experience irritability or drowsiness, the decision to breastfeed while taking desloratadine should be made in consultation with a pediatrician. In many cases, it is considered 'probably compatible' with breastfeeding, but monitoring the infant for symptoms is essential.

Desloratadine is approved for children as young as 6 months of age. It is one of the few antihistamines with safety data for such young infants. However, it is not approved for use in children under 6 months.

• Growth Effects: There is no evidence that long-term use of desloratadine affects growth or development in children.
• Dosing: It is critical to use the oral solution for children under 6 to ensure precise weight-based or age-based dosing.

Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. However, in general, elderly patients are more likely to have decreased renal or hepatic function.

• Fall Risk: Although non-sedating, any drug that can cause slight dizziness or fatigue may increase the risk of falls in the elderly.
• Polypharmacy: Older adults often take multiple medications; therefore, the risk of drug-drug interactions is higher.

In patients with chronic kidney disease (CKD), the clearance of desloratadine is significantly reduced.

• Mild to Moderate: Dosing every other day is usually sufficient.
• End-Stage Renal Disease (ESRD): Desloratadine is not effectively removed by hemodialysis. Patients on dialysis should be monitored very closely for adverse effects if desloratadine is used.

In patients with hepatic impairment (e.g., cirrhosis), the half-life of desloratadine can be significantly prolonged. The Child-Pugh score may be used by clinicians to determine the severity of liver disease. For most patients with liver impairment, the 'every other day' dosing rule applies to prevent the drug from reaching toxic concentrations in the blood.

> Important: Special populations require individualized medical assessment. Never share your medication with others, especially those in these sensitive categories.

Desloratadine is a selective H1-receptor antagonist that exhibits a unique pharmacological profile. Unlike first-generation antihistamines, it has a very low affinity for the muscarinic, adrenergic, and serotonergic receptors, which accounts for its reduced side-effect profile (less dry eye, less urinary retention).

At the molecular level, desloratadine binds to the H1 receptor with high affinity. It is considered an inverse agonist, meaning it shifts the equilibrium of the H1 receptor from its active state to its inactive state. This effectively prevents the downstream signaling that leads to the 'allergic cascade.' Furthermore, desloratadine's slow dissociation rate from the receptor contributes to its long duration of action, allowing for 24-hour symptom relief with a single dose.

• Onset of Action: Relief of symptoms typically begins within 1 to 3 hours after oral administration.
• Duration: The effects persist for at least 24 hours.
• Tolerance: There is no evidence of tachyphylaxis (rapidly diminishing response) or the development of tolerance with daily use over 28 days.
• Cardiac Effects: At doses up to 9 times the recommended dose (45 mg), desloratadine does not cause clinically significant prolongation of the QTc interval.

| Parameter | Value |

|---|---|

| Bioavailability | Not precisely quantified in humans; unaffected by food |

| Protein Binding | 82% to 87% (Desloratadine); 85% to 89% (3-OH metabolite) |

| Half-life | ~27 hours |

| Tmax | ~3 hours |

| Metabolism | Hepatic (Hydroxylation to 3-hydroxydesloratadine) |

| Excretion | Renal 41%, Fecal 47% |

• Molecular Formula: C19H19ClN2
• Molecular Weight: 310.82 g/mol
• Solubility: Slightly soluble in water; very soluble in ethanol and propylene glycol.
• Structure: Desloratadine is a tricyclic compound, specifically a des-carboethoxy analogue of loratadine. It contains a chlorine atom on the benzene ring which contributes to its potency.

Desloratadine is classified as a Second-Generation Antihistamine and a H1-Receptor Antagonist [EPC]. It is therapeutically related to other non-sedating antihistamines such as loratadine, cetirizine, and fexofenadine. Among these, desloratadine is often noted for having the longest half-life and the highest receptor affinity.